| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED OCTOBER 2014. Refer toTA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | dabrafenib (Tafinlar®) | |
| Formulation | 50 mg and 75 mg capsule | |
| Reference number | 1844 | |
| Indication | Monotherapy for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation |
|
| Company | GlaxoSmithKline | |
| BNF chapter | Malignant disease & immunosuppression | |
| Assessment type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 27/02/2014 | |
| Date of issue | 27/02/2014 | |
| NICE guidance | TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
|